Price
$7.95
Decreased by -0.38%
Dollar Volume
674.78 K
ADR%
6.29
Earnings Report Date (estimate)
Mar 15, 23 (-0.27)
Market Cap.
365.02 M
Shares Float
18.21 M
Shares Outstanding
45.91 M
Beta
1.31
Price / Earnings
-4.55
BPR
221.30
20D Range
7.28 8.90
50D Range
5.81 8.90
200D Range
4.82 9.95
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.42
Increased by +23.64%
-0.10
Decreased by -320.00%
Aug 11, 22 -0.60
Decreased by -30.43%
-0.39
Decreased by -53.85%
May 12, 22 -0.25
Increased by +44.44%
-0.19
Decreased by -31.58%
Mar 17, 22 -0.52
Decreased by -92.59%
-0.30
Decreased by -73.33%
Nov 10, 21 -0.55
Decreased by -96.43%
0.01
Decreased by -5.60 K%
Aug 10, 21 -0.46
Increased by +13.21%
-0.40
Decreased by -15.00%
May 13, 21 -0.45
Decreased by -50.00%
-0.36
Decreased by -25.00%
Mar 18, 21 -0.27
Increased by +18.18%
-0.31
Increased by +12.90%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 8.37 M
Decreased by -1.75%
-13.27 M
Increased by +1.64%
Decreased by -158.64%
Decreased by -0.11%
Jun 30, 22 5.29 M
Decreased by -26.43%
-18.10 M
Decreased by -64.09%
Decreased by -341.99%
Decreased by -123.04%
Mar 31, 22 13.63 M
Increased by +325.37%
-7.53 M
Increased by +29.28%
Decreased by -55.23%
Increased by +83.37%
Dec 31, 21 -3.99 M
Decreased by -170.64%
-15.17 M
Decreased by -139.15%
Increased by +380.51%
Increased by +438.57%
Sep 30, 21 8.52 M
Increased by +345.16%
-13.49 M
Decreased by -119.88%
Decreased by -158.45%
Increased by +50.61%
Jun 30, 21 7.19 M
Increased by +945.49%
-11.03 M
Decreased by -11.09%
Decreased by -153.33%
Increased by +89.37%
Mar 31, 21 3.20 M
Increased by +193.68%
-10.64 M
Decreased by -92.35%
Decreased by -332.18%
Increased by +34.50%
Dec 31, 20 5.64 M
Increased by +538.35%
-6.34 M
Decreased by -3.29%
Decreased by -112.39%
Increased by +83.82%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.